Abcam (NASDAQ:ABCM) Shares Gap Down to $16.19

Abcam plc (NASDAQ:ABCMGet Rating) shares gapped down before the market opened on Tuesday . The stock had previously closed at $16.19, but opened at $15.47. Abcam shares last traded at $15.32, with a volume of 2,585 shares.

Analysts Set New Price Targets

ABCM has been the subject of several analyst reports. Royal Bank of Canada boosted their target price on Abcam from GBX 1,700 ($20.10) to GBX 2,200 ($26.01) in a research note on Wednesday, September 14th. Panmure Gordon raised Abcam from a “hold” rating to a “buy” rating in a research note on Monday, September 5th.

Abcam Trading Up 2.1 %

The stock has a fifty day simple moving average of $15.51 and a 200-day simple moving average of $14.92.

Institutional Trading of Abcam

A number of institutional investors have recently bought and sold shares of the business. Advisors Capital Management LLC lifted its holdings in Abcam by 3.8% during the 3rd quarter. Advisors Capital Management LLC now owns 64,234 shares of the company’s stock worth $1,078,000 after buying an additional 2,342 shares during the last quarter. Balyasny Asset Management LLC purchased a new stake in Abcam during the 3rd quarter worth about $163,000. Jane Street Group LLC purchased a new stake in Abcam during the 3rd quarter worth about $216,000. Neuberger Berman Group LLC lifted its holdings in Abcam by 6.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 293,094 shares of the company’s stock worth $4,393,000 after buying an additional 18,064 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in Abcam by 2.5% during the 3rd quarter. Alliancebernstein L.P. now owns 207,693 shares of the company’s stock worth $3,113,000 after buying an additional 5,125 shares during the last quarter. 11.82% of the stock is owned by hedge funds and other institutional investors.

Abcam Company Profile

(Get Rating)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.

Read More

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.